Effects of selective and nonselective alpha-1-adrenoceptor antagonists on intraurethral and arterial pressures in intact conscious dogs

Pharmacology

Volumn 53, Issue 6, 1996, Pages 356-368

  Brune, Michael E ^a   Katwala, Sweta P ^a   Milicic, Ivan ^a   Buckner, Steven A ^a   Ireland, Lynne M ^a   Kerwin, James F ^a   Hancock, Arthur A ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Alpha adrenoceptor subtypes; Benign prostatic hyperplasia

Indexed keywords

8 [3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]PROPYLCARBAMOYL] 3 METHYLFLAVONE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; DOXAZOSIN; PHENYLEPHRINE; RADIOLIGAND; RECEPTOR SUBTYPE; TAMSULOSIN; TERAZOSIN;

ANIMAL EXPERIMENT; ARTICLE; BALLOON CATHETER; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG RECEPTOR BINDING; INTRAVENOUS DRUG ADMINISTRATION; LIGAND BINDING; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; TELEMETRY; URETHRA PRESSURE;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BLOOD PRESSURE; DOGS; DOXAZOSIN; MALE; PRAZOSIN; PROSTATIC HYPERPLASIA; SULFONAMIDES; TIME FACTORS; URETHRA;

EID: 0030447950     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139451     Document Type: Article

References (38)

1. Boyle P. Napalkov P: The epidemiology of benign proslalie hyperplasia and observations on concomitant hypertension. Scand.1 Urol Nephrol 1995:29:7-12.
2. Holtgrcwe HL. Ackcrmann K. Bay-Nielsen H: The economics of BPH: in Cockett ATK. et al (eds): Proc SCI. The Second Intcrnationl Consultation on Benign Prostatic Hyperplasia (BPH). Paris. June 27-50. 1993. pp 35-45.
3. Janknegt RA. Chappie CR: Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Eur Urol 1993:24:319-326.
4. Chappie CR. Carter P. Christmas TJ. Kirby RS. Bryan J. Milroy EJG. Abrams P: A three-month double-blind study of doxazosin as treatment for benign prostatie bladder outlet obstruction. Br.1 Urol 1994: 74:50-56.
5. Rochborn CG. Ocstcrling IE. Auerbach S. Kaplan SA. Keith Lloyd L. Milam DF. Padley RJ. for the HY-CAT Investigator Group: The Hytrin community assessment trial study: A one-vear study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 1996:47: 159-168.
6. Hillman AL. Schwartz JS. Willian MK. Pcskin E. Rochborn CG. Ocstcrling JE. Mason ME. Maurath CJ. Dcvcrka PA. Padlcv RJ: The cost-effectivencss of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Urology 1996:47:169-178.
7. Lepor H. Tang R. Meretyk S. Ilar-lanto V. Shapiro E: Binding and functional properties of alphai-adre-noccplors and area density of smooth muscle in the canine prostate. Urol 1992:148:1310-1313.
8. Lepor Z. Zhang W. Kobayashi S. Tang R. Wang B. Shapiro E: A comparison of the binding and functional properties of alpha-1 adrenoceptors and area density of smooth muscle in the human, canine and rat prostates. J Pharmacol Exp Tiler 1994:270:722-727.
9. James S. Chappie CR. Phillips ML Burnstock G: Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in hyperplastic human prostate. J Urol 1989;142:438-444.
10. Kobayashi H. Tang R. Shapiro E. Lepor H: Characterization of prostatic alphai adrenoceptors using radioligand binding on slide mounted tissue sections. J Urol 1993:150: 2002-2006.
11. Lepor H. Baumann M. Shapiro E: Identification and characterization of alphai-adrenergic receptors in the canine prostate using '-1 heat. J Urol 1992:938:1336-1339.
12. Maruyama K. Tsuchihashi H, Baba S. Mano F. NagatomoT: Ui-Adreno-ccptor subtypes in bovine prostate. J Pharm Pharmacol 1992:44:727-730.
13. Caine M. Raz S. Zeiglcr M: Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975;47:193-202.
14. Hieble JP. Boyce AJ. Caine M: Comparison of the alpha adrenoceptor characteristics in human and canine prostate. Fed Proc 1986:45: 2609-2614.
15. Hieble JP. Caine M. Zalaznik E: In vitro characterization of the alpha-adrenoceptors in human prostate. Eur J Pharmacol 1985:107:111-117.
16. Kvncl JJ. Sonders RC. Sperzel WD, Winn M, Seely JH: Terazosin; in Scriabine A (ed): New Cardiovascular Drugs. New York. Raven Press, 1986. pp 1-18.
17. Campbell SF. Davey MJ. Hardstonc JD, Lewis BN. Palmer MJ: 2,4-Diamino-6.7-dimethoxyquinazol-incs. 1. 2-[4-(1.4-Benzodioxan-2-vl-carbonyl)piperazin-l-yl) derivatives as ai-adrenoceptor antagonists and antihypertensive agents. J Med Client 1987:30:49-57.
18. McGrath JC: Evidence for more than one type of postjunctional al-pha-adrenoceptor. Biochem Pharmacol 1982;31:467-484.
19. Hieble JP, DeMarninis RM, Matthews WD: Evidence for and against heterogeneity of ot-adrcnoccptors. LifeSci 1986:38:1339-1350.
20. 2+. Pharmacol Rev 1988;40:87-119.
21. Lomansey JW, Cottecchia S, Lorenz W, Leung WY. Schwinn DA. Yang-Feng T, Brownstein M, Lcfkowitz RJ, Caron MC: Molecular cloning and expression of the cDNA for the alpha 1A adrenergic receptor. J Biol Chem 1991;266:6365-6369.
22. Cotecchia S. Schwinn DA. Randall R. Lefkowitz RJ. Caron MC. Kobii-ka BK: Molecular cloning and expression of the cDNA for the hamster alpha 1 adrenergic receptor. Proc Natl Acad Sei USA 1988;85: 7159-7163.
23. Schwinn DA. Lomansey J W. Lorenz W, Szklut PJ, Frcmeau PT. Yang-Feng T. Caron MC. Lcfkowitz RJ. Cottecchia S: Molecular cloningand expression of the cDNA of a novel alpha 1 adrenergic receptor subtype. J Biol Chem 1990:265:8183-8189.
24. C sub-type. Molec Pharmacol 1994:45: 703-708.
25. Marshall I. Burt RP. Andersson PO. Chappie CR. Grccngrass PM. Johnson GI. Wyllic MG: Human ale adrenoceptor: Functional characterization in prostate. Br J Pharmacol 1992; 107:327P.
26. Bylund DB. Eikenburg DC. Hieble JP. Langer SZ, Lcfkowitz RJ. Minneman KP, Molinoff PB. Ruffo-lo RR Jr. Trendelenburg IV: International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 1994:46:121-136.
27. Brune ME. Buckner SA. Polakowski J, Kerwin JF. Hancock AA: Pharmacological antagonism of o-adren-ergic agonist induced increases in canine intraurethral pressure in vivo. Drug Dev Res 1995:34:267-275.
28. Buckner SA. Oheim KW. Morse PA. Kncppcr SM. Hancock AA: ar Adrenoceptor-i nduced contract ility in rat aorta is mediated by the aid subtype. Eur J Pharmacol 1996:297: 241-248.
29. A receptor subtype. J Pharmacol ExpTher 1995;274:97-103.
30. Kawabe K: Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia. Br J Urol 1995:76:63-67.
31. Recordati's urologicals disappoint. Scrip. May 13,1996.
32. Dcklcrk DP. Coflev DS, Ewing LL. McDermott JR, Reiner WG. Robinson CH. Scott WW. Strandberg JD. Talalay P. Walsh PC. Wheaton LG. Zirkin BR: Comparison of spontaneous and experimentally induced canine prostatic hyperplasia. J Clin Invest 1979:64:842-849.
33. Testa R. Poggesi E. Taddei C, Guar-neri L. lbba M. Leonardi A: Rec 15/ 2739. a new ai-antagonist selective for the lower urinary tract: In vitro studies. Ncurourol Urodyn 1994:13: 473-474.
34. Michel MC. Buscher R, Kerker J, Kraneis H. Erdbrugger W. Brodde O: u I-Adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Arch Pharmacol 1993;348:385-395.
35. Takcnaka T, Fujikura T, Honda K. Asano M. Nigata K: Discovery and development of tamsulosin hydrochloride. a new ai-adrenoceptor antagonist. Yakugaku Zasshi 1995; 115:773-789.
36. Testa R. Sironi G. Colombo D. Gre-to L. Leonardi A: Rec 15/2739, a new ai-antagonist selective for the lower urinary tract: In vivo studies. Ncurourol Urodyn 1994:13:471-472.
37. Kenny BA. Naylor AM. Carter AJ, Read AM. Greengrass PM. Wvllie MG: Effect of alpha 1 adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog. Urology 1994:44:52-57.
38. Vargas HM, Gorman AJ: Vascular alpha-1 adrenergic receptor sub-types in the regulation of arterial pressure. Life Sci 1995:57:2291-2308.